Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, phase I/II study. In the phase I, patients with Human
Epidermal Growth Factor Receptor 2 (HER2) positive MBC will be treated with paclitaxel,
trastuzumab and increasing doses of dasatinib to determine the Maximum Tolerated Dose (MTD),
Dose Limiting Toxicity (DLT) and Recommended Phase II Dose (RPD) of the combination. Once the
RPD has been identified, 48 patients will be treated at that dose to evaluate the efficacy
and safety of the combination in the phase II.